How do you approach local therapy for oligoprogression of metastatic NSCLC?

Tsai et al. presented data from the CURB trial at ASTRO 2021. This showed a significant improvement in median PFS (44 vs 9 weeks) for NSCLC patients with oligoprogression (unlimited mets at presentation and 5 or less mets on progression) randomized to SBRT vs best supportive care. Interestingly, the...

At the University of Colorado, we have very frequently treated such a patient with stereotactic body radiation therapy (SBRT), or hypofractionated or conventional radiation therapy if SBRT is not possible. Unfortunately, there is not as much published literature to support this approach as any of us...